Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer J. 2009 Mar-Apr;15(2):161-3. doi: 10.1097/PPO.0b013e3181a1438a.

Salvage therapy for Hodgkin's lymphoma.

Author information

1
Section of Hematology and Oncology, UNMC Oncology/Hematology Section, 987680 Nebraska Medical Center, University of Nebraska, Omaha, NE, USA. fquddus@unmc.edu

Abstract

Hodgkin's lymphoma (HL) is a clonal lymphoid malignancy that affects over 7000 patients in the United States annually. The disease remains one of the great success stories in the recent history of cancer treatment. More than 80% of HL patients will be expected to be long-term survivors because of recent advances in radiation therapy and combined chemotherapy. However, for the subset of patients who relapse after initial therapy, HL remains a challenging disease. Indeed, for patients who relapse after salvage high-dose chemotherapy and autologous stem cell transplant, effective therapeutic options remain limited, and further new therapies are warranted. This article provides a review of the current literature regarding salvage therapy for HL.

PMID:
19390313
DOI:
10.1097/PPO.0b013e3181a1438a
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Support Center